In these trials, specific inhibitors of different isoforms of PI3K, pan PI3K inhibitors, Akt-inhibitors or mTOR-inhibitors are evaluated in different settings commonly in association with trastuzumab and chemotherapy to delay breast cancer progression and/or overcome resistance to trastuzumab. This evidence concerns the gene PIK3CA and breast cancer.